Dupilumab for COPD with Type 2 Inflammation Indicated by Eosinophil Counts – New England Journal of Medicine (link to abstract – $ for full-text) Commentary: Dupilumab Improves Outcomes for COPD, Type 2 Inflammation in Randomized Trial – HCP Live   Commentary on Twitter Presented at #ATS2023: In the BOREAS trial, dupilumab resulted in a lower […]

The post RCT | Dupilumab improves lung function and reduces exacerbations in COPD patients with elevated eosinophils appeared first on Links Medicus.